Tagged with Investment,

university The executive director of Latin America’s largest plasma fractionation plant, a publicly-funded laboratory within the 400 year old National University of Cordoba, discusses the organization’s social responsibility as a provider and leader for plasma derived therapies in the region, and their exciting pipeline of innovative biotech products.     How does Hemoderivados’s…

innovation The general manager of BI Algeria discusses how Algeria could benefit from participating in international clinical trials and describes how his company is adapting its offering to mirror the changing health profile of the nation which is currently undergoing a transition from infectious and transmissible disease to chronic and lifestyle illnesses.…

research The director general for Scientific Research and Technological Development discusses the authorities’ efforts to incentivize R&D and to harmonize sectoral development strategies to achieve national economic growth outcomes. He also identifies bottlenecks in the human capital base and the importance of raising the intellectual and scientific level of the local…

Deloitte In the second part of this interview, the managing partner of Deloitte Algeria sheds light on opportunity and risk in the Algerian pharma market. He explains the distorting effect of strict joint venture rules and outlines the many challenges in navigating Algeria’s regulatory and legal frameworks while at the same time…

consulting The managing partner of one of the “big four” consultancies speaks out about market entry strategies for Algeria and how Deloitte itself went about servicing the local pharmaceuticals industry among other thriving economic sectors. As a member of the “Big Four” professional services firms, what sort of offering does Deloitte…

chamber of commerce The European Chamber of Commerce in Korea (ECCK) was founded in 2012, in order to represent the interests of European businesses in Korea. Christoph Heider, secretary general of ECCK, discusses the initial challenges involved in establishing the chamber, as well as his outlook on the challenges and opportunities that the…

investment Newcomers to Algeria’s fledgling, but increasingly vibrant pharmaceuticals sector are immediately struck by the sense of liveliness pervading the industry. Indeed, as growth patterns in developed markets continue to flatten, and the protagonists of ‘big pharma’ pivot towards securing new revenue sources in emergent economies, Algeria must surely constitute one…

innovation Joaquin Poch, president of the Royal Academy of Medicine of Spain, outlines the Academy’s history and current initiatives.   What are the objectives of the Royal Academy of Medicine and what are your own personal objectives as president? In order to answer this question we have to go back to…

biotech Bioceres manages investments in agricultural biotechnology and related sciences. The company’s CEO, Federico Trucco, discusses the potential of Argentina’s biotech scene to become a world-class drug developer in biopharma as well as Bioceres’ own investments in the sector.   How did you become involved with Bioceres? I have known the…

family business Adrian Fernandez, current CEO, shares his experience of taking a domestic company international and the viability of the family business model in the contemporary market.   As a rapidly internationalizing company, how much of a burden have regulatory barriers between countries placed on your business? Its not too much of…

pain management Mundipharma Malaysia’s country manager discusses his company’s aim to become a reference in Malaysia for pain management, on the back of the tremendous 48 percent growth of the business last year.    Mundipharma has recently entered a booming Malaysian pharmaceutical sector. What are your first impressions of the Malaysian market? Malaysia’s pharmaceutical sector…

Pfizer Edgardo Vázquez, Pfizer’s country manager for the Argentina Region, discusses the company’s investment strategies across their newly established business units and a few of the unique challenges presented by the Argentinean market.   How have Pfizer’s goals for Argentina changed over the last few years, and what is your strategy…